Last reviewed · How we verify
progesterone 600mg
Progesterone 600mg, marketed by Universitair Ziekenhuis Brussel, holds a niche position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection offered by its patent, which helps maintain its competitive edge. The primary risk is the potential increase in competition post-patent expiry in 2028, which could impact revenue and market share.
At a glance
| Generic name | progesterone 600mg |
|---|---|
| Sponsor | Universitair Ziekenhuis Brussel |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Deep Learning Method to Evaluate QT on Ribociclib
- Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles (PHASE3)
- MIcronized PROgesterone in Frozen Embryo Transfer Cycles (PHASE3)
- Prediction and Prevention of Twin Premature Birth 2021 (PHASE4)
- Luteal Support and Intrauterine Insemination (IUI) With Clomiphene Citrate (NA)
- Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- progesterone 600mg CI brief — competitive landscape report
- progesterone 600mg updates RSS · CI watch RSS
- Universitair Ziekenhuis Brussel portfolio CI